ImCheck Therapeutics logo

ImCheck Therapeutics

ImCheck Therapeutics is developing a new generation of proprietary immuno-modulatory antibodies acting on both adaptive and innate immunity (notably gamma-delta T-cells).

ImCheck is a spin-off from C.R.C.M., Marseilles Cancer Research Center (IPC, CNRS, Inserm, AMU), and was founded around discoveries of Prof. Daniel Olive, Prof. of Immunology at Aix-Marseille University & Institut Paoli-Calmettes. ImCheck has secured worldwide exclusive IP rights for its pipeline from Inserm Transfert and SATT-SE.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.imchecktherapeutics.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
180 Avenue Du Prado, 13008
Marseille
United States
Email
Contact Number
+33 6 62 22 00 24

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/imcheck-therapeutics” connections=”true” suffix=””]

In May 2017, ImCheck Therapeutics raised ‹20 Mn in Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest and joined by Gimv and LSP.

In Sep 2017, ImCheck recieved a non equity diluting funding award of ‹930,000 from Bpifrance to contribute to the advancement of one of its novel immunotherapy program in cancer. The funding will be dedicated to conducting translational studies and launching the production of a novel therapeutic antibody active on both adaptive and innate immune cells and whose target remains confidential at this stage.